[ad_1]
KUALA LUMPUR (November 5): Bintai Kinden Corp Bhd’s partner, Generex Biotechnology Corp, has signed a framework agreement for the development and commercialization of the coronavirus II-Key-SARS-CoV-2 vaccine in China.
In a statement today, Bintai Kinden said that his partner signed the agreement with the Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.
He said Generex will receive upfront development fees and payment for back-end licenses under the framework agreement.
The partners will carry out research and development (R&D) and pay 100% of the funds required for commercial approval of the Ii-Key-SARS-CoV-2 vaccine, including laboratory work, manufacturing, regulatory registries and the clinical development program for regulatory approval of the vaccine in China.
Bintai Kinden said that the Ii-Key-SARS-CoV-2 vaccine is designed as a “complete vaccine” with the potential to induce T-cell and antibody immune responses in a very specific way that can provide protective immunity with long-lasting immune memory against the SARS. -CoV-2 and other pandemic threats such as Covid-19 and swine flu.
Bintai Kinden Managing Director Ong Choon Lui said the partnership between Generex, the China CDC, Beijing Guoxin Haixiang and Beijing Youfeng reaffirmed the potential of Ii-Key technology for immune system regulation to develop safe and effective vaccines. for infectious diseases and cancer.
“The involvement of China’s state fund and cooperation at the highest level of government through the China CDC increase the likelihood of success of the vaccine commercialization efforts,” he added.
Bintai Kinden’s subsidiary, Bintai Healthcare Sdn Bhd, in October signed a distribution and license agreement with Generex and its subsidiary NuGenerex Immuco-Oncology Inc for its Covid-19 vaccine in Malaysia.
Under the agreement, Bintai Kinden said, Bintai Healthcare has the exclusive rights to distribute, sell and market the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.
“You will also have the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market,” said Bintai Kinden.
At the time of writing, Bintai Kinden’s shares had risen one sen or 1.54% to 66 sen, bringing its market capitalization to RM 210.07 million.
[ad_2]
